R.j. Reynolds Tobacco Company

Reneo Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Inflazome Limited

Kiora Pharmaceuticals, Inc.

Escape Bio, Inc.

Susana Del Rio Gancedo

Gary Maurice Dull

Osama Suleiman

Judit Galcera Julia

Emma Sharp

Julie Ann Macrae

Neil Feeder

Joseph Stephen Harris

Cristina Balogh

Rachael Lee

Louis Grenier

David Miller

Daniel G Genov

Stéphane De Lombaert

Angus Macleod

Scott Lawrence Childs

Samuel Stratford

Alexander Redvers Eberlin

Stefan Sperl

Andrew Hague

Michael A Christie

Ludovic Sylvain Marc Renou

Ana Rosario Mool Sarno

Edward L Ciolkowski

Lucy Kristina Mapp

Mateusz Bogumil Pitak

Lisa Plasser

Christopher Daniel Scott

The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.

Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The invention further provides methods of preparation and characterization of nicotine salts, co-crystals, and salt co-crystals. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

Nicotine salts, co-crystals, and salt co-crystal complexes

Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR&#x3b4; agonist compound.

Crystalline PPAR&#x3b4; agonist

This application relates to solid forms of an S1P-receptor modulator, which are useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders.

Solid forms of an S1P-receptor modulator

Crystalline PPAR-delta agonist

The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

Sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof.

Salts and solid forms of isoquinolinones and composition comprising and methods of using the same

Growing community of inventors

Cambridge, United Kingdom

Susana Del Rio Gancedo